Chargement des cours...
Prévisions
Aucune donnée d'analyste n'est disponible pour cette entreprise.
Actualités Accéder au fil d'actualités
Silo Pharma receives Canadian patent approval for PTSD compound SPC-15
The Canadian Intellectual Property Office has issued a notice of allowance for the patent application for SPC-15, an intranasal 5‑HT4 receptor agonist for PTSD. Silo Pharma holds the exclusive license for the application in Canada under a global licensing agreement with Columbia University. The company reports that related patents have already been granted or are under review in other markets and plans to pursue US approval via the FDA 505(b)(2) pathway. » Plus sur de.investing.com
Silo Pharma receives European patent for intranasal PTSD therapy SPC-15
The European Patent Office has granted patent EP3952852 for SPC-15, an intranasal prophylaxis to prevent PTSD and stress-related affective disorders via serotonin-4 receptor agonists. Silo Pharma holds an exclusive license from Columbia University for worldwide development, manufacture and commercialization and positions SPC-15 as a “nose-to-brain” intervention to bolster stress resilience prior to trauma exposure. The European patent expands the existing patent portfolio for SPC-15, which already has protection in five other markets. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | juin 2026 | |
|---|---|---|
| Chiffre d'affaires | 0 | 100,00 % |
| Bénéfice brut | -2,57 k | 118,32 % |
| Bénéfice net | -729,73 k | 28,58 % |
| EBITDA | -866,38 k | 14,92 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 2,47 M € |
Nombre d'actions | 1,13 M |
Plus haut/bas sur 52 semaines | 13,08 € - 2,10 € |
| Dividendes | Non |
Bêta | 0,80 |
Ratio P/E | -0,47 |
Ratio PEG | 0,00 |
Ratio P/B | 0,57 |
Ratio P/S | 53,01 |
Profil de l'entreprise
| Nom | Silo Pharma Inc |
| PDG | Eric Weisblum |
| Employés | 3 |
Découvrir des actifs
Les actionnaires de Silo Pharma Inc investissent également dans les actifs suivants
